CRESCENT BIOPHARMA, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CRESCENT BIOPHARMA, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2016 | $18.5K | Mar 6, 2018 |
| FY2017 | Sep 30, 2016 | $18.5K | Mar 6, 2018 |
| FY2016 | Dec 31, 2015 | $35.4K | Mar 1, 2017 |
| FY2016 | Jun 30, 2015 | $20.04M | Mar 1, 2017 |
| FY2016 | Dec 31, 2014 | $15.03M | Mar 1, 2017 |
| FY2015 | Jun 30, 2014 | $15.03M | Feb 29, 2016 |
| FY2014 | Dec 31, 2013 | $77.4K | Mar 16, 2015 |
| FY2014 | Sep 30, 2013 | $52.6K | Mar 16, 2015 |
| FY2014 | Jun 30, 2013 | $55.1K | Mar 16, 2015 |
| FY2014 | Mar 31, 2013 | $3.81M | Mar 16, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.84M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Feb 26, 2026 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($153.94M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($17.87M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($36.90M) | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | ($46.69M) | Mar 27, 2024 |
| FY2023 | Dec 31, 2021 | ($63.43M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | ($51.03M) | Mar 29, 2023 |
| FY2019 | Dec 31, 2019 | ($14.73M) | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | ($13.25M) | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | ($15.83M) | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | ($14.08M) | Feb 28, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($152.63M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($17.19M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($39.28M) | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | ($47.40M) | Mar 27, 2024 |
| FY2023 | Dec 31, 2021 | ($63.45M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | ($51.51M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | ($61.39M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | ($51.50M) | Mar 2, 2021 |
| FY2019 | Dec 31, 2017 | ($33.93M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | ($31.91M) | Mar 6, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $138.09M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $14.03M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $20.07M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $28.39M | Mar 27, 2024 |
| FY2023 | Dec 31, 2021 | $47.49M | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $44.93M | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | $47.03M | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | $40.09M | Mar 2, 2021 |
| FY2019 | Dec 31, 2017 | $24.10M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $23.28M | Mar 6, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $6.60M | Mar 16, 2015 |
| FY2014 | Dec 31, 2013 | $2.90M | Mar 16, 2015 |
| FY2014 | Dec 31, 2012 | $2.18M | Mar 16, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($71.53M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($6.27M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($34.88M) | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | ($46.46M) | Mar 27, 2024 |
| FY2023 | Dec 31, 2021 | ($57.49M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | ($39.24M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | ($51.98M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | ($43.33M) | Mar 2, 2021 |
| FY2019 | Dec 31, 2017 | ($29.77M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | ($29.73M) | Mar 6, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $919.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $21.4K | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $84.2K | Mar 27, 2024 |
| FY2023 | Dec 31, 2021 | $14.9K | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $68.5K | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | $144.9K | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | $125.6K | Mar 2, 2021 |
| FY2019 | Dec 31, 2017 | $294.1K | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $704.2K | Mar 6, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $240.29M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $35.62M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $45.32M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $51.81M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $94.35M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $142.83M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $167.97M | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | $214.84M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $128.58M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $42.39M | Mar 6, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.28M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $47.10M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $6.90M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $8.88M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $12.74M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $14.61M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $13.77M | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | $9.37M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $8.88M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $7.09M | Mar 6, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $203.01M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($15.48M) | Feb 26, 2026 |
| FY2025 | Sep 19, 2024 | $0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $38.41M | Feb 13, 2025 |
| FY2024 | Dec 31, 2022 | $42.93M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $81.60M | Mar 27, 2024 |
| FY2023 | Dec 31, 2020 | $128.22M | Mar 27, 2024 |
| FY2022 | Dec 31, 2019 | $154.20M | Mar 29, 2023 |
| FY2021 | Dec 31, 2018 | $205.46M | Mar 3, 2022 |
| FY2020 | Dec 31, 2017 | $119.70M | Mar 2, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($171.81M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($17.87M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($456.49M) | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | ($419.59M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($372.90M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($309.47M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | ($258.44M) | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | ($200.55M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | ($152.28M) | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | ($118.98M) | Mar 6, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $213.19M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $34.77M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $41.79M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $47.87M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $90.25M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $137.04M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $158.20M | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | $209.92M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $123.92M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $40.04M | Mar 6, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Feb 13, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 27, 2024 |
| FY2023 | Dec 31, 2021 | (1) | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Mar 3, 2022 |
| FY2016 | Dec 31, 2015 | 0 | Mar 1, 2017 |
| FY2016 | Sep 30, 2015 | 0 | Mar 1, 2017 |
| FY2016 | Jun 30, 2015 | 0 | Mar 1, 2017 |
| FY2016 | Mar 31, 2015 | 0 | Mar 1, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Feb 13, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 27, 2024 |
| FY2023 | Dec 31, 2021 | (1) | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Mar 3, 2022 |
| FY2016 | Dec 31, 2015 | 0 | Mar 1, 2017 |
| FY2016 | Sep 30, 2015 | 0 | Mar 1, 2017 |
| FY2016 | Jun 30, 2015 | 0 | Mar 1, 2017 |
| FY2016 | Mar 31, 2015 | 0 | Mar 1, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 27.56M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 1.02M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 64.39M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | 54.38M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 52.31M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | 49.02M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | 43.47M | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | 43.16M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | 34.36M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | 23.25M | Mar 6, 2018 |